nach oben

Erschienen in:

01.09.2014 | Laboratory Investigation

Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas

verfasst von: J. M. Dueñas Jiménez, A. Candanedo Arellano, A. Santerre, S. Orozco Suárez, H. Sandoval Sánchez, I. Feria Romero, R. López-Elizalde, M. Alonso Venegas, B. Netel, B. de la Torre Valdovinos, S. H. Dueñas Jiménez

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Estrogens are oncogenic hormones at a high level in breast, prostate, endometrial and lung cancer. Estrogens are synthesized by aromatase which has been used as a biomarker both in breast and lung cancer. Estrogen biological activities are executed by their classic receptors (ERα and ERβ). ERα has been described as a cancer promoter and ERβ, as a possible tumor suppressor. Both receptors are present at low levels in primary multiforme glioblastoma (GBM). The GBM frequency is 50 % higher in men than in women. The GBM patient survival period ranges from 7 to 18 months. The purpose of this pilot study was to evaluate aromatase and estrogen receptor expression, as well as 17ß-estradiol concentration in astrocytoma patients biopsies to obtain a prognosis biomarker for these patients. We analyzed 36 biopsies of astrocytoma patients with a different grade (I–IV) of malignity. Aromatase and estrogen receptor mRNA expression were analyzed by semiquantitative RT-PCR, and the E2 levels, by ELISA. E2 concentration was higher in GBM, compared to grade II or III astrocytomas. The number of cells immunoreactive to aromatase and estrogen receptors decreased as the grade of tumor malignity increased. Aromatase mRNA expression was present in all biopsies, regardless of malignity grade or patient age or gender. The highest expression of aromatase mRNA in GBM patients was associated to the worst survival prognostic (6.28 months). In contrast lowest expression of ERα mRNA in astrocytoma patients had a worst prognosis. In conclusion, aromatase and ERα expression could be used as prognosis biomarkers for astrocytoma patients.

Inskip PD, Linet MS, Heineman EF (1995) Etiology of brain tumors in adults. Epidemiol Rev 17:382–414PubMed

McKinley BP, Michalek AM, Fenstermaker RA et al (2000) The impact of age and sex on the incidence of glial tumors in New York State from 1976 to 1995. J Neurosurg 93:932–939PubMedCrossRef

Kabat GC, Etgen AM, Rohan TE (2010) Do steroid hormones play a role in the etiologyof glioma? Cancer Epidemiol Biomarkers Prev 19:2421–2427PubMedCrossRef

Silvera SA, Miller AB, Rohan TE (2006) Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 118:1321–1324PubMedCrossRef

Gual C, Morato T, Hayano M et al (1962) Biosynthesis of estrogens. Endocrinology 71:920–925PubMedCrossRef

Roselli CE, Liu M, Hurn PD (2009) Brain aromatization: classical roles and new perspectives. Semin Reprod Med 27:207–217PubMedCentralPubMedCrossRef

Yague JG, Lavaque E, Carretero J et al (2004) Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas. Neurosci Lett 368:279–284PubMedCrossRef

Oyama T, Sugio K, Isse T et al (2008) Expression of cytochrome P450 in non-small cell lung cancer. Front Biosci 13:5787–5793PubMedCrossRef

Camara-Quintana JQ, Nitta RT, Li G (2012) Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 23:237–246PubMedCrossRef

10.

Kabat G (2004) Effect of public smoking ban in Helena, Montana: When results look too good to be true, they probably are. BMJ 328:1376–1380

11.

Batistatou A, Stefanou D, Goussia A et al (2004) Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol 130:405–410PubMed

12.

Deyrup AT, Tretiakova M, Khramtsov A et al (2004) Estrogen receptor beta expression in vascular neoplasia: an analysis of 53 benign and malignant cases. Mod Pathol 17:1372–1377PubMedCrossRef

13.

Konstantinopoulos PA, Kominea A, Vandoros G et al (2003) Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 39:1251–1258PubMedCrossRef

14.

Pujol P, Rey JM, Nirde P et al (1998) Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367–5373PubMed

15.

Speirs V (2002) Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? J Pathol 197:143–147PubMedCrossRef

16.

Kefalopoulou Z, Tzelepi V, Zolota V et al (2012) Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognostic. J Neurooncol 106:23–31PubMedCrossRef

17.

Sareddy GR, Nair BC, Gonugunta VK et al (2012) Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther 11:1174–1182PubMedCentralPubMedCrossRef

18.

Patel S, DiBiase S, Meisenberg B et al (2012) Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. Int J Rad Oncol Biol Fis 82:739–742CrossRef

19.

Bulun SE, Lin Z, Zhao H et al (2009) Regulation of aromatase expression in breast cancer tissue. Annual NY Acad Sci 1155:121–131CrossRef

20.

van Duursen MB, Nijmeijer SM, de Morree ES et al (2011) Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model. Toxicology 289:67–73PubMedCrossRef

21.

Lifrange E, Andre C, Bleret V et al (2011) Hormone therapy for breast cancer. Rev Med Liege 66:367–371PubMed

22.

Fowler JM, Ramirez N, Cohn DE et al (2005) Correlation of Cy-clooxygenase-2 (COX-2) an aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstretics Gynecol 192:1262–1271CrossRef

23.

Márquez-Garbán DC, Chen HW, Goodglick L et al (2009) Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann NY Acad Sci 1155:194–205PubMedCentralPubMedCrossRef

24.

Samarajeewa NU, Docanto MM, Simpson ER et al (2013) CREB-regulated transcription co-activator family stimulates promoter II-driven aromatase expression in preadipocytes. Horm Cancer 4:233–241PubMedCrossRef

25.

Areshkov PA, Kavsan VM (2010) Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87 MG) cells. Tsitol Genet 44:3–9PubMed

26.

Arevalo MA, Diz-Chaves Y, Santos-Galindo M et al (2012) Selective oestrogen receptor modulators decrease the inflammatory response of glial cells. J Neuroendocrinol 24:183–190PubMedCrossRef

27.

Carroll RS, Dashner K, Sar M et al (1995) Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 37:496–503PubMedCrossRef

28.

Green S (1986) A superfamily of potentially oncogenic hormone receptors. Nature 324:615–617PubMedCrossRef

29.

Brentani MM, Martins VR, Plese JP (1984) Steroid receptors in intracranial tumors. Clin Neuropharmacol 7:347–350PubMedCrossRef

30.

Paoletti P, Zibera C et al (1990) Characteristics and biological role of steroid hormone receptors in neuroepithelial tumors. J Neurosurg 73:736–742PubMedCrossRef

31.

González-Agüero G, Ondarza R, Gamboa-Dominguez A et al (2001) Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res Bull 56:43–48PubMedCrossRef

32.

Batistatou A, Kyzas PA, Goussia A et al (2006) Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognostic in brain glial tumours. J Neurooncol 77:17–23PubMedCrossRef

33.

Nojima D, Li LC, Dharia A et al (2001) CpG hypermethylation of the promoter region inactivates the estrogen receptor-b gene in patients with prostate carcinoma. Cancer 92:2076–2083PubMedCrossRef

34.

González-Arenas A, Hansberg-Pastor V, Hernández-Hernández OT et al (2012) Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators. Biochim Biophys Acta 1823:379–386PubMedCrossRef

35.

Berny W, Weiser A, Jarmundowicz W et al (2004) Analysis of expression of estrogen (ER) and progesterone receptors (PR) in brain glial tumors and its correlation with expression of p53 protein and proliferating cell nuclear antigen (PCNA). Neurol Neurochir Pol 38:367–371PubMed

36.

Pietras RJ, Márquez DC, Chen HW et al (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70:372–381PubMedCrossRef

37.

Niikawa H, Suzuki T, Suzuki S et al (2008) Intratumoral estrogens and estrogen receptors in non-small cell lung carcinoma. Clin Cancer Res 14:4417–4426PubMedCrossRef

38.

Abe K, Miki Y, Sugawara S, Suzuki T et al (2010) Highly concordant coexpression of aromatase and estrogen receptor β in non-small cell lung cancer. Hum Pathol 41:190–198PubMedCrossRef

39.

Mah V, Seligson DB, Li A, Márquez DC et al (2007) Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res 67:10484–10490PubMedCentralPubMedCrossRef

40.

Oyama T, Kagawa N, Sugio K et al (2009) Expression of aromatase CYP19 and its relationship with parameters in NSCLC. Front Biosci 14:2285–2292CrossRef

41.

Miki Y, Suzuki T, Abe K et al (2010) Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res 70:6659–6669PubMedCrossRef

42.

Weinberg OK, Marquez-Garban DC, Fishbein MC et al (2005) Aromatase inhibitors in human lung cancer therapy. Cancer Res 65:11287–11291PubMedCrossRef

43.

Esteban JM, Warsi Z, Haniu M et al (1992) Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 140:337–343PubMedCentralPubMed

44.

Bulun SE, Price TM, Aitken J et al (1993) A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77:1622–1628PubMed

45.

Sasano H, Nagura H, Harada N et al (1994) Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 25:530–535PubMedCrossRef

46.

Santen RJ, Martel J, Hoagland M et al (1994) Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 79:627–632PubMed

47.

Utsumi T, Harada N, Maruta M et al (1996) Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J Clin Endocrinol Metab 81:2344–2349PubMed

48.

Lu Q, Nakmura J, Savinov A et al (1996) Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137:3061–3068

49.

Sasano H, Edwards DP, Anderson TJ et al (2003) Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. J Steroid Biochem Mol Biol 86:239–244

50.

Suzuki T, Miki Y, Nakamura Y et al (2005) Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 12:701–720

Titel: Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas
verfasst von: J. M. Dueñas Jiménez
A. Candanedo Arellano
A. Santerre
S. Orozco Suárez
H. Sandoval Sánchez
I. Feria Romero
R. López-Elizalde
M. Alonso Venegas
B. Netel
B. de la Torre Valdovinos
S. H. Dueñas Jiménez
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1509-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema

Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors

Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant

Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation

A young boy with a paravertebral mass and symptoms of spinal compression